1. Medtech Insight
  2. >>Archive

NICE Guidance: Prostatic Implants, RF Ablation For Snoring, Transcranial Stimulation For Migraine, Arthroscopic Kneecap Surgery

The influential U.K. institute approves the use of prostatic urethral lift implants to treat urinary symptoms in men with benign prostatic hyperplasia, as well as radiofrequency ablation of the soft palate to treat snoring. Transcranial magnetic stimulation for migraine and arthroscopic trochleoplasty to treat patellar instability don’t fare as well.

NeoTract Inc. is celebrating a conclusion by the U.K.’s National Institute for Health and Care Excellence that the insertion of prostatic urethral lift implants to treat urinary tract symptoms in men with benign prostatic hyperplasia is safe and efficacious. NICE’s January interventional procedure guidance says that studies involving 391 men showed that the implants significantly improved the patients’ ability to pass urine. The procedure is designed to cause less tissue injury than surgical resection or thermal ablation, and is claimed to reduce the risk of complications such as sexual dysfunction and incontinence, according to NICE. However, the guidance also notes that the implant, like other treatment options, is unlikely to permanently relieve symptoms.

Pleasanton, Calif.-based NeoTract markets the UroLift prostatic lift implant in Europe, Australia and Canada. The device works by holding the prostate lobes in a retracted position, allowing the obstructed urethra...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.